The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

EXODIAB – strategic research

Researchers at LUDC are part of EXODIAB (Excellence of Diabetes Research in Sweden), a strategic research area at Lund University. The aim of EXODIAB is to develop new treatments and drugs to prevent or cure diabetes.

The primary aim of EXODIAB is to develop new treatments and drugs that can prevent, delay, or cure diabetes and its complications. A second objective is to create improved conditions for the personalisation of care and treatment of patients with diabetes.

Platforms for collaboration

EXODIAB is a joint strategic research initiative in the diabetes area at Lund University and Uppsala University, and at LUDC more than 300 members of staff are involved in this collaborative effort.

The strategic research area integrates research in various fields with clinical studies and population studies (epidemiology) and creates platforms for collaboration between academia and industry.  

EXODIAB is funded by a strategic research grant from the Swedish Research Council.

Link to a list of research output in Lund University’s research portal

Link to a list of projects within EXODIAB in Lund University’s research portal

Link to a list of members of staff who are affiliated with EXODIAB in Lund University’s research portal
 

Contact

Portrait of Allan Vaag. Photograph.

Allan Vaag
Professor and Coordinator of LUDC and EXODIAB
allan [dot] vaag [at] med [dot] lu [dot] se

Portrait of Lena Eliasson. Photograph.

Lena Eliasson
Professor and Vice Coordinator of LUDC and EXODIAB
lena [dot] eliasson [at] med [dot] lu [dot] se
+46 (0)40 39 11 53
+46 (0)70 522 54 14